yingweiwo
  1. Home
  2. Products
  3. Signaling Pathways
  4. New Products
  5. NEW3
  6. New3

insulin lispro

Cat No.:V41694 Purity: ≥98%
COA Product Data Instructions for use SDS
Insulin lispro is a recombinant human insulin analog and one of three rapid-acting insulin analogs.
insulin lispro
insulin lispro Chemical Structure CAS No.: 133107-64-9
Product category: New3
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
Other Sizes
1-708-310-1919 sales@invivochem.com
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
Insulin lispro is a recombinant human insulin analog and one of three rapid-acting insulin analogs. Insulin lispro may be utilized in the research/study of diabetic hyperglycemia.
Biological Activity I Assay Protocols (From Reference)
References

[1]. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs. 2007;67(3):407-34.
Additional Infomation
Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
See also: Insulin Lispro (annotation moved to).
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C158H234N40O42S2.C99H155N25O35S4
Molecular Weight
5813.61785999995
Exact Mass
5811.691
CAS #
133107-64-9
PubChem CID
16132438
Appearance
White to off-white solid powder
Hydrogen Bond Donor Count
84
Hydrogen Bond Acceptor Count
89
Rotatable Bond Count
185
Heavy Atom Count
405
Complexity
13000
Defined Atom Stereocenter Count
52
SMILES
[H]/N=C(/NCCC[C@@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@H](C(=O)O)[C@H](O)C)=O)CCC1)=O)CCCCN)=O)[C@H](O)C)=O)CC1=CC=C(O)C=C1)=O)CC1=CC=CC=C1)=O)CC1=CC=CC=C1)=O)=O)NC([C@@H](NC(CNC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@H](CC1=CC=CC=C1)N)=O)=O)CC(=O)N)=O)CCC(=O)N)=O)CC1N=CNC=1)=O)CC(C)C)=O)CS)=O)=O)CO)=O)CC1N=CNC=1)=O)CC(C)C)=O)=O)CCC(=O)O)=O)C)=O)CC(C)C)=O)CC1=CC=C(O)C=C1)=O)CC(C)C)=O)=O)CS)=O)=O)CCC(=O)O)=O)\N.CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CC(=O)N)=O)CS)=O)CC1=CC=C(O)C=C1)=O)CC(=O)N)=O)CCC(=O)O)=O)CC(C)C)=O)CCC(=O)N)=O)CC1=CC=C(O)C=C1)=O)CC(C)C)=O)CO)=O)CS)=O)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@H]([C@H](CC)C)NC(CN)=O)=O)=O)CCC(=O)O)=O)CCC(=O)N)=O)CS)=O)CS)=O)=O)CO)=O)C
InChi Key
WNRQPCUGRUFHED-DETKDSODSA-N
InChi Code
InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1
Chemical Name
(4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 0.1720 mL 0.8600 mL 1.7201 mL
5 mM 0.0344 mL 0.1720 mL 0.3440 mL
10 mM 0.0172 mL 0.0860 mL 0.1720 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
CTID: NCT05893797
Phase: N/A    Status: Completed
Date: 2024-11-29
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
CTID: NCT05462756
Phase: Phase 3    Status: Completed
Date: 2024-08-22
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
CTID: NCT06280703
Phase: Phase 1    Status: Recruiting
Date: 2024-05-31
Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique
CTID: NCT03229850
Phase: N/A    Status: Suspended
Date: 2024-05-08
Simplified Insulin Regimen for the Elderly
CTID: NCT03660553
Phase: Phase 4    Status: Terminated
Date: 2023-12-12
View More

Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal
CTID: NCT04019821
Phase: Phase 4    Status: Completed
Date: 2023-11-30

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
CTID: NCT04537923
Phase: Phase 3    Status: Completed
Date: 2023-11-02
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
CTID: NCT05834868
Phase: Phase 3    Status: Recruiting
Date: 2023-04-28
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
CTID: NCT03952130
Phase: Phase 3    Status: Completed
Date: 2023-02-08
Effects of Insulin on Hypotension and Sarcopenia
CTID: NCT03248271
Phase:    Status: Withdrawn
Date: 2023-01-12
A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)
CTID: NCT04816890
Phase: Phase 2    Status: Completed
Date: 2022-06-24
Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
CTID: NCT01613807
Phase: Phase 4    Status: Completed
Date: 2022-06-08
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
CTID: NCT03952143
Phase: Phase 3    Status: Completed
Date: 2022-02-08
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
CTID: NCT03740919
Phase: Phase 3    Status: Completed
Date: 2022-01-24
A Study of LY900014 in Healthy Chinese Participants
CTID: NCT04049123
Phase: Phase 1    Status: Completed
Date: 2021-11-16
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
CTID: NCT04276207
Phase: Phase 1    Status: Completed
Date: 2021-08-25
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
CTID: NCT03338023
Phase: Phase 3    Status: Completed
Date: 2021-03-29
Feasibility Trial Testing the Bionic Pancreas With ZP4207
CTID: NCT02971228
Phase: Phase 2    Status: Completed
Date: 2021-03-23
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
CTID: NCT03830281
Phase: Phase 3    Status: Completed
Date: 2021-01-22
Comparison of Insulins Aspart and Lispro in Insulin Pumps
CTID: NCT00461331
Phase: Phase 4    Status: Completed
Date: 2021-01-08
A Study of LY900014 in a Medtronic Pump
CTID: NCT03760640
Phase: Phase 2    Status: Completed
Date: 2020-10-29
A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus
CTID: NCT04161976
Phase: Phase 1    Status: Completed
Date: 2020-08-05
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
CTID: NCT03465878
Phase: Phase 1    Status: Completed
Date: 2020-06-18
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
CTID: NCT02703337
Phase: Phase 1    Status: Completed
Date: 2020-06-17
A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy
CTID: NCT02703350
Phase: Phase 1    Status: Completed
Date: 2020-06-17
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
CTID: NCT02703324
Phase: Phase 1    Status: Completed
Date: 2020-06-17
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
CTID: NCT03341312
Phase: Phase 1    Status: Completed
Date: 2020-06-09
A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
CTID: NCT02770521
Phase: Phase 1    Status: Completed
Date: 2020-06-04
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
CTID: NCT03305822
Phase: Phase 1    Status: Completed
Date: 2020-05-27
A Study of a New LY900014 Formulation in Healthy Participants
CTID: NCT02525744
Phase: Phase 1    Status: Completed
Date: 2020-05-19
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus
CTID: NCT03341299
Phase: Phase 1    Status: Completed
Date: 2020-05-14
A Study of LY900014 Formulations in Healthy Participants
CTID: NCT02317575
Phase: Phase 1    Status: Completed
Date: 2020-05-13
A Study of Various Formulations of LY900014 in Healthy Participants
CTID: NCT02636361
Phase: Phase 1    Status: Completed
Date: 2020-05-13
A Study of LY900014 in Participants With Type 1 Diabetes
CTID: NCT03214367
Phase: Phase 3    Status: Completed
Date: 2020-05-01
A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
CTID: NCT03407118
Phase: Phase 1    Status: Completed
Date: 2020-05-01
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
CTID: NCT03056456
Phase: Phase 1    Status: Completed
Date: 2020-05-01
A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants
CTID: NCT03286751
Phase: Phase 1    Status: Completed
Date: 2020-05-01
A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus
CTID: NCT03166124
Phase: Phase 1    Status: Completed
Date: 2020-04-30
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
CTID: NCT03449433
Phase: Phase 1    Status: Completed
Date: 2020-04-30
A Study of LY900014 Formulation in Healthy Participants
CTID: NCT02942654
Phase: Phase 1    Status: Completed
Date: 2020-04-27
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
CTID: NCT03214380
Phase: Phase 3    Status: Completed
Date: 2020-03-27
The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.
CTID: NCT04124302
Phase: Phase 4    Status: Unknown status
Date: 2019-10-11
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
CTID: NCT03433677
Phase: Phase 3    Status: Completed
Date: 2019-10-08
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
CTID: NCT04100473
Phase: Phase 2    Status: Completed
Date: 2019-09-24
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
CTID: NCT01621178
Phase: Phase 3    Status: Completed
Date: 2019-09-19
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
CTID: NCT03307512
Phase: Phase 2    Status: Terminated
Date: 2019-09-13
Assessment of Mealtime Bolus Insulin Behavior
CTID: NCT03368807
Phase:    Status: Completed
Date: 2019-08-02
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
CTID: NCT03890003
Phase: N/A    Status: Completed
Date: 2019-06-05
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
CTID: NCT03849612
Phase: N/A    Status: Completed
Date: 2019-04-25
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges
CTID: NCT03848767
Phase: N/A    Status: Completed
Date: 2019-04-23
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
CTID: NCT02152384
Phase: Phase 1    Status: Completed
Date: 2019-03-01
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
CTID: NCT01194245
Phase: Phase 2    Status: Completed
Date: 2019-02-26
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
CTID: NCT01526733
Phase: Phase 4    Status: Completed
Date: 2019-02-26
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
CTID: NCT03743285
Phase: N/A    Status: Completed
Date: 2019-02-19
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
CTID: NCT01848990
Phase: Phase 4    Status: Completed
Date: 2018-11-07
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
CTID: NCT02197520
Phase: Phase 1    Status: Completed
Date: 2018-11-01
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
CTID: NCT03682640
Phase: Phase 2    Status: Unknown status
Date: 2018-09-24
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
CTID: NCT00803972
Phase: Phase 1    Status: Completed
Date: 2018-08-15
Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)
CTID: NCT02794155
Phase: Phase 2    Status: Completed
Date: 2018-07-31
A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects
CTID: NCT03604575
Phase: N/A    Status: Completed
Date: 2018-07-27
Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes
CTID: NCT03509324
Phase: Phase 4    Status: Completed
Date: 2018-04-26
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
CTID: NCT01792284
Phase: Phase 3    Status: Completed
Date: 2018-04-20
Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
CTID: NCT01662921
Phase: Phase 2    Status: Completed
Date: 2018-04-18
A Study in Participants With Type 2 Diabetes Mellitus
CTID: NCT01468987
Phase: Phase 3    Status: Completed
Date: 2018-04-17
A Study in Participants With Type 1 Diabetes Mellitus
CTID: NCT01481779
Phase: Phase 3    Status: Completed
Date: 2018-04-17
A Study in Participants With Type I Diabetes Mellitus
CTID: NCT01454284
Phase: Phase 3    Status: Completed
Date: 2018-04-17
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
CTID: NCT03367390
Phase: Phase 1    Status: Completed
Date: 2018-03-15
Normal Versus Dual Wave Insulin Bolus for High-protein Food
CTID: NCT02276859
Phase: Phase 4    Status: Completed
Date: 2018-01-31
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients
CTID: NCT01035801
Phase: Phase 1    Status: Terminated
Date: 2018-01-23
A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy
CTID: NCT02623452
Phase: Phase 1    Status: Withdrawn
Date: 2017-07-13
A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy
CTID: NCT02623465
Phase: Phase 1    Status: Withdrawn
Date: 2017-07-13
A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
CTID: NCT02623478
Phase: Phase 1    Status: Withdrawn
Date: 2017-07-13
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus
CTID: NCT02470637
Phase: Phase 1    Status: Completed
Date: 2017-04-13
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
CTID: NCT00097071
Phase: Phase 3    Status: Completed
Date: 2016-12-22
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
CTID: NCT00071448
Phase: Phase 3    Status: Completed
Date: 2016-12-22
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
CTID: NCT02739906
Phase: Phase 1/Phase 2    Status: Completed
Date: 2016-08-18
Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
CTID: NCT02685449
Phase: Phase 4    Status: Unknown status
Date: 2016-07-29
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
CTID: NCT00115570
Phase: Phase 3    Status: Completed
Date: 2016-05-20
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
CTID: NCT02603510
Phase: Phase 1    Status: Completed
Date: 2016-05-19
Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes
CTID: NCT02526810
Phase: Phase 4    Status: Unknown status
Date: 2015-08-20
Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.
CTID: NCT00849576
Phase: Phase 3    Status: Completed
Date: 2015-08-03
A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus
CTID: NCT01235039
Phase: Phase 1/Phase 2    Status: Completed
Date: 2015-07-29
A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants
CTID: NCT02111083
Phase: Phase 1    Status: Completed
Date: 2015-05-21
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
CTID: NCT00960661
Phase: Phase 3    Status: Completed
Date: 2015-04-07
Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
CTID: NCT01776788
Phase: Phase 4    Status: Completed
Date: 2015-03-10
A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1
CTID: NCT02221323
Phase: Phase 2    Status: Completed
Date: 2014-12-30
A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes
CTID: NCT02273258
Phase: Phase 1    Status: Completed
Date: 2014-10-23
A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
CTID: NCT01871493
Phase: Phase 1    Status: Completed
Date: 2014-10-21
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
CTID: NCT00700622
Phase: Phase 3    Status: Terminated
Date: 2014-10-16
A Study in Adults With Type 1 Diabetes
CTID: NCT01421147
Phase: Phase 3    Status: Completed
Da
AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2019-10-23
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA, Completed
Date: 2019-03-29
I8B MC ITRO
CTID: null
Phase: Phase 3    Status: Completed
Date: 2019-03-18
A Randomized, Open-Label, 4-Period Cross-Over Study to Investigate the Inter- and Intra-subject Variability of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects with Type 1 Diabetes Mellitus (T1DM)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-11-27
A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects with Type 1 Diabetes Mellitus (T1DM)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-11-27
A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare
CTID: null
Phase: Phase 3    Status: Ongoing, Prematurely Ended
Date: 2018-10-24
A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-05-16
Protocol I8B-MC-ITSI
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-12-27
Evaluation of different algorithms for the calculation of the prandial insulin dose, considering the fat and protein content of the meal - Effects on postprandial glucose in type 1 diabetes patients with insulin pump therapy
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-08-01
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-08-01
Protocol I8B-MC-ITRN
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-06-07
Impact on oxidative stress of novel analogues of insulin in people with type 1 diabetes. Low- intervention clinical trial. Ineox Study
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-11-03
A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF THE ACUTE ADMINISTRATION OF THE SGLT-2 INHIBITOR CANAGLIFLOZIN ON CONTERREGULATORY RESPONSE TO INSULIN-INDUCED HYPOGLYCEMIA
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2016-10-27
Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus also Using Insulin Glargine
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-02-11
Blood glucose control with BC222 insulin lispro compared to insulin lispro (Humalog®) after ingestion of a standardised meal.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2015-01-06
Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-11-19
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Period
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-11-12
A trial to compare the pharmacokinetics and pharmacodynamics of insulin lispro administered s.c. into lipohypertrophic or normal abdominal adipose tissue in subjects with diabetes mellitus type 1
CTID: null
Phase: Phase 2    Status: Completed
Date: 2014-09-15
A double-blinded, randomised, three-period crossover euglycaemic clamp trial investigating the pharmacokinetics, glucodynamics and safety of BC222 human insulin, human insulin (Huminsulin® Normal) and insulin lispro (Humalog®) in subjects with type 1 diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2014-07-07
A double-blinded, randomised, four -period crossover euglycemic clamp trial investigating the dose-response and dose-exposure relationship of BC222 insulin lispro in three different doses in subjects with type 1 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2014-05-12
Samba-02: An Investigation of the Dose-Response and Subject Variability of Inhaled Insulin in Subjects with Type 2 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-09-24
Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects with Type 1 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-03-28
Treat-To-Target Trial of Continuous Subcutaneous , sensor-augmented insulin-pump therapy in new-onset diabetes after transplantation (SAPT-NODAT): Efficacy and Safety of an Intensive Insulin Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-01-14
An open, single-centre, non-controlled feasibility study using a softwarealgorithm based insulin therapy to control blood glucose in type 1 diabetic patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-01-07
Protocol I2R-MC-BIAN (a)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-03-05
Efficacy and mechanisms of a short course of intensified insulin treatment on remission or responsiveness to oral therapy in type 2 diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-03-01
Protocol I2R-MC-BIAM
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-01-24
Protocol I2R-MC-BIAO
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-12-02
A Prospective, Randomized, Open-Label Comparison of a
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-09-12
Two Approaches to Escalate Lispro Therapy in Patients with Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-02-07
A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-09-09
The Effect of Postprandial Hyperglycemia on Arterial Stiffness in Patients with Type 2 Diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-06-16
A single center, open-label, randomized study examining the glycemic effects of intra-dermal vs. subcutaneous bolus dosing of insulin lispro in patients with type 1 diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2010-04-06
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-01-29
Prevention of Recurrent Severe Hypoglycaemia: a Definitive RCT Comparing Optimised MDI and CSII with or without Adjunctive Real-time Continuous Glucose Monitoring.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-01-28
A mono-center, open label, randomised 2-period crossover study to compare the pharmacokinetics and pharmacodynamics of continuous insulin infusion administered either intradermally or subcutaneously in subjects with type 1 diabetes mellitus
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-12-23
A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults with Type 1 Diabetes: Novel Pen with Memory Function (HumaPen® Memoir) vs. Conventional Pen without Memory Function
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-09-11
A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects with Type 1 Diabetes Mellitus
CTID: null
Phase: Phase 1, Phase 2    Status: Completed
Date: 2009-07-10
A Randomized Trial Comparing two therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 Diabetes who were previously treated by basal insulin Glargine with either Metformin or Metformin and Sulfonylurea
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-06-18
Effect of prandial treatment with insulin VIAjectTM compared to regular human insulin and insulin lispro on postprandial endothelial function and microvascular stress in type 2 diabetic patients
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-04-22
A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-02-13
ESTUDIO COMPARATIVO DEL TRATAMIENTO CON BOMBA DE INSULINA SUBCUTANEA, INSULINA GLARGINA E INSULINA NPH EN NIÑOS DIABÉTICOS DE 0 A 6 AÑOS DE EDAD
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-02-01
Comparación de un régimen de insulina lispro premezclada (proporción baja, 25/75; y proporción media, 50/50) con un régimen de inyecciones separadas de insulina basal y en bolos, en pacientes con diabetes tipo 2 que consumen un desayuno ligero y presentan un control glucémico insuficiente con tratamiento oral
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-01-25
Comparison of Technosphere®/Insulin, Insulin Lispro and Exubera® Effect on Endogenous Glucose Production After a Meal Challenge and During a Euglycemic Glucose Clamp Procedure in Subjects with Type 2 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-12-27
A mono center, open-label glucose clamp study examining the metabolic effect of the frequency of insulin infusion intervals for basal insulin infusion in patients with type 1 diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-12-13
Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-11-13
A mono center, open-label, randomized study examining the effects of intra-dermal vs. subcutaneous application of regular human insulin or rapid-acting insulin analogue on postprandial glycemic excursions in patients with type 1 diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-09-14
Estudio PERSISTENT: Estudio prospectivo y aleatorizado en el que se compara la suspensión de insulina lispro con protamina con la insulina glargina en pacientes con diabetes tipo 2 que reciben medicaciones antidiabéticas
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-08-03
-----------------------

Contact Us
Tel: 1-708-310-1919 Fax: 1-708-557-7486 Email: sales@invivochem.com Frequently Asked Questions
Subscribe to our E-newsletter
Name
E-mail

Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved

linkedin facebook
Contact Us
Home Product Cart Member